Compare Novo Nordisk A/S (NVO) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Taskus Inc — how do they compare? Novo Nordisk A/S trades at $38.16 (market cap $165.31B), while Taskus Inc trades at $7.99 (market cap $723.41M). The key difference: Novo Nordisk A/S is far larger — about 228.5× Taskus Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Taskus Inc for 34 Days on average.
| NVO | TASK | |
|---|---|---|
Market Cap | $165.31B | $723.41M |
Volume | 11,432,838 | 201,303 |
Sector | Health | Technology |
52-Week High | $63.98 | $14.69 |
52-Week Low | $35.29 | $4.57 |
Typical Hold Time | 116 Days | 34 Days |
Enterprise Value | $179.56B | $1.09B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
TaskUs trades at $7.89, down 0.88% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin of 8.75%. Valuation metrics appear attractive with P/E of 6.8 and P/S of 0.6. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected. Analyst consensus is bullish with 55% buy ratings and $9.33 price target, representing 18% upside potential.
The stock presents value opportunity with solid profitability and AI services growth offsetting Trust & Safety declines. Key risks include labor cost pressures and client concentration. Positive cash flow generation and institutional accumulation support the bullish case, though technical weakness suggests near-term consolidation may continue before potential breakout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
